Clinical trial NCT03160521: Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia
Official title: Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Acute Schizophrenia
Lead sponsor: Rovi Pharmaceuticals Laboratories
Sponsor class: INDUSTRY
First posted: 2017-05-19
Enrollment: 438
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of intramuscular (IM) injections of Risperidone ISM® (75 or 100 mg) or placebo, in patients with acute exacerbation of schizophrenia.

Detailed description: The study design includes a screening period, a 12-week treatment period, and a follow-up period. Eligible patients will be randomly assigned, under double-blind conditions, to receive the following study drug treatments in a 1:1:1 ratio during the double-blind treatment period: Risperidone ISM® 75 mg, Risperidone ISM® 100 mg, or placebo. The IM study drug (double-blind active Risperidone ISM® or placebo) will be administered in a deltoid or gluteal muscle for a total of 3 times, once every 4 weeks, during the 12-week treatment period.

If indicated for an individual patient, prohibited medications may be washed out during the screening period. Patients who have never taken Risperidone must have a brief trial of oral Risperidone in order to ensure a lack of any clinically significant hypersensitivity reactions before the first dose of the study drug is administered.

Efficacy will be assessed by describing changes in scores on standard psychiatric assessment tools at each visit. Safety assessments will also be conducted at each visit.

The primary objective of this study is the following:

• To evaluate the efficacy of Risperidone ISM as compared with that of placebo in the treatment of patients with acute exacerbation of schizophrenia

The secondary objectives of this study are the following:

* To characterize safety and tolerability of Risperidone ISM as compared with that of placebo in patients with acute exacerbation of schizophrenia
* To quantify healthcare resource utilization (HRU), health-related quality of life (HRQL), and social functioning in patients treated with Risperidone ISM versus placebo for an acute exacerbation of schizophrenia
* To explore pharmacokinetic characteristics of Risperidone ISM and associations with efficacy

Patients who complete planned double-blind study drug treatments and study evaluations may be eligible to participate in an optional long-term extension segment of the study in which treatment with open-label Risperidone ISM 75 or 100 mg (randomly assigned) would begin immediately; for patients who do not participate in the extension segment, a safety follow-up phone contact will occur after the end-of-treatment visit.

In addition to patients continuing from the double-blind segment of the study (rollover patients), patients not previously enrolled in the study (de novo patients) may be eligible to enter the long-term extension segment of the study. These patients will be evaluated for eligibility at a screening visit and, if eligible, will be allocated to receive either 75 or 100 mg Risperidone ISM every 4 weeks for approximately 12 months.

Eligibility criteria: Inclusion Criteria:

To be eligible for enrolment into the study, each patient must meet all of the following criteria at screening:

1. Capable of providing informed consent

   1. A signed informed consent form must be provided before any study assessments are performed
   2. Patients must be fluent in the language that is spoken by the investigator and the study site staff (including raters) and must be able to read and understand the words in which the informed consent is written
2. Age ≥ 18 and ≤ 65 years
3. Body mass index 18.5 to 40.0 kg/m2 (inclusive)
4. Current diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria

   1. Currently experiencing an acute exacerbation or relapse with onset \< 2 months before screening
   2. If inpatient at screening, has been hospitalized for \< 2 weeks for the current exacerbation
   3. ≥ 2 years have elapsed since initial onset of active-phase schizophrenia symptoms
5. Has been able to achieve outpatient status for \> 4 months during the past year
6. Has previously had a clinically significant beneficial response (improvement in schizophrenia symptoms), as determined by the investigator, to treatment with an antipsychotic medication other than clozapine
7. Agrees to discontinue prohibited medications as applicable and as clinically indicated according to investigator instructions
8. Dosages of all permitted medications are considered to have been stable (with the exception of medication to be used on an as-needed basis) for ≥ 2 weeks prior to the baseline visit and to remain stable during participation in this study
9. Positive and Negative Syndrome Scale (PANSS) results at the screening and baseline visits meets the following criteria:

   a. Total score between 80 and 120, inclusive b. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale items: i. Item 1 (P1: delusions) ii. Item 2 (P2: conceptual disorganization) iii. Item 3 (P3: hallucinatory behavior) iv. Item 6 (P6: suspiciousness/persecution)
10. Clinical Global Impression - Severity (CGI-S) score of ≥ 4 (moderately ill or worse)
11. Resides in a stable living situation and is anticipated to return to that same stable living situation after discharge from the inpatient study unit, in the opinion of the investigator
12. Has an identified reliable informant who is anticipated to remain the same after the patient is discharged from the inpatient study unit, in the opinion of the investigator
13. Meets the following criteria:

    a. If a sexually active, is using a medically accepted contraceptive method, and will continue to use such throughout participation in this study (and for ≥ 6 months after the last dose of IM study drug has been administered); acceptable methods include the following: i. Condoms (male or female) with or without a spermicidal agent ii. Diaphragm or cervical cap with spermicide iii. Intrauterine device iv. Hormonal contraceptive b. If not currently sexually active, them meets the following criteria: i. Agrees that if sexually activity resumes while participating in this study, a medically accepted contraception method will be used
14. Willing and able to be confined to an inpatient study unit for up to 2 weeks (or longer if clinically indicated), as applicable and as clinically indicated according to investigator instructions
15. Agrees not to post any personal medical data related to the study or information related to the study on any website or social media site (eg, Facebook, Twitter, and others) during the study duration

Exclusion Criteria:

An individual who meets any of the following criteria at screening will not be permitted to enroll in the study:

1. History of proven inadequate clinical response to treatment with therapeutic doses (with good compliance) of risperidone or paliperidone
2. History of treatment resistance, defined as failure to respond to 2 discrete adequate trials (≥ 4 weeks with an adequate dose) of 2 different antipsychotic medications; history of clozapine use (exception: use was not because of treatment resistance or refractory psychotic symptoms)
3. Improvement in PANSS total score 20% or greater between the initial screening visit and first injection
4. Known or suspected intolerance of or allergy or hypersensitivity to risperidone, paliperidone, or any of the excipients in the IM formulations of these
5. History of neuroleptic malignant syndrome, clinically significant tardive dyskinesia, or tardive dystonia
6. History of any other medical condition that is considered to pose any unjustifiable risk or interfere with study assessments
7. Clinically significant extrapyramidal symptoms at screening or baseline
8. Answer of "yes" on item 4 or on item 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) (ideation) with the most recent episode occurring within the past 2 months, or answer "yes" to any of the 5 items (behavior) with an episode occurring within the last year
9. Current diagnosis or a history of substance use disorder according to DSM-5 criteria within 6 months prior to the screening visit (with the exception of tobacco, mild cannabis, or mild alcohol use disorder) or a positive drug screen test (with the exception of cannabis) verified by repeat testing
10. Lifetime history of diagnosis of schizoaffective disorder or bipolar disorder
11. Clinically significant comorbid neuropsychiatric disorders including any of the following:

    1. Current untreated or unstable major depressive disorder
    2. Clinically significant cognitive difficulties including dementia, delirium, or amnesic syndrome, within the past 2 years and would interfere with participation in the study
    3. Any other psychiatric condition that would, in the judgment of the investigator, interfere with participation in the study
12. Clinically significant or unstable medical illness/condition/disorder that would be anticipated, in the investigator's opinion, to potentially compromise patient safety or adversely affect the evaluation of efficacy, including (but not necessarily limited to) the following:

    1. Clinically significant hypotension or hypertension not stabilized by medical therapy (diastolic blood pressure \> 105 mmHg)
    2. Unstable thyroid dysfunction in the past 6 months
    3. Malignant tumor within the last 5 years
    4. Neurologic conditions including the following:

    i. History of seizure disorder or condition associated with seizures ii. History of brain tumor, subdural hematoma, or other clinically significant neurological condition within the past 12 months iii. Head trauma with loss of consciousness within 12 months before screening iv. Active acute or chronic central nervous system infection v. Stroke within 6 months before screening e. Cardiac conditions including the following: i. Clinically significant cardiac arrhythmia, cardiomyopathy, or cardiac conduction defect ii. History of myocardial infarction or unstable angina within the last 3 months before screening, or clinically significant abnormality on screening or baseline electrocardiogram (ECG) including but not limited to the following: QT interval corrected for heart rate using Fridericia's formula (QTcF) \> 465 msec if male or \> 485 msec if female
13. Laboratory abnormality that, in the opinion of the investigator, would compromise the well-being of the patient, or any of the following laboratory abnormalities at screening or baseline:

    1. Aspartate aminotransferase or alanine aminotransferase value ≥ 2 times the upper limit of the laboratory normal reference range
    2. Hemoglobin A1c \> 9%
    3. Absolute neutrophil count ≤ 1.5 × 103 μL
    4. Platelet count ≤ 75 × 103 μL
    5. Creatinine clearance \< 60 mL/min
    6. Positive test result for human immunodeficiency virus, hepatitis B surface antigen, or antihepatitis C virus antibody
    7. Positive pregnancy test result
    8. Urine drug screen at screening or baseline shows a positive result for any of the tested substances (potential exceptions: results positive for benzodiazepine may not be exclusionary if the investigator confirms that such medication was medically indicated and consults the medical monitor before enrolling a patient with such a finding; results positive for Tetrahydrocannabinol (THC) may not be exclusionary in certain cases only if exclusion criterion 9 is not met and only if the medical monitor provides approval)
14. Pregnant, lactating, or breastfeeding
15. Inadequate gluteal or deltoid musculature or excessive fat, as determined by the investigator, that would interfere with IM study drug injections
16. Any contraindication for IM injections
17. Receipt of any long-acting antipsychotic medication by IM injection within 60 days before screening
18. Current involuntary hospitalization or incarceration
19. Hospitalized for more than 30 days during the 90 days before screening
20. Participation in another clinical study in which the patient received an experimental or investigational drug or agent within 6 months before screening
21. Participation in a clinical study with Risperidone ISM within 1 year before screening
22. Study site personnel and/or persons employed by the investigator or study site or is an immediate family member of such persons
23. Patients taking any prohibited concomitant medication (see Section 3.2.2.1.1) at the time of randomization visit
24. Clinically significant ocular disease or visual impairment interfering with the planned ophthalmological examinations or that in the investigator's opinion could potentially compromise patients' ocular safety
25. Patients with planned or anticipated need for ocular surgery during the treatment period of the trial

Primary outcomes:
measure: PANSS Total Score Mean Change From Baseline to Endpoint
timeFrame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Secondary outcomes:
measure: CGI-S Total Score Mean Change From Baseline to Endpoint
timeFrame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
measure: CGI-I Score Mean at Endpoint
timeFrame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
measure: Overall Response Rate at Endpoint
timeFrame: Day 85 or the last post-baseline assessment
measure: PANSS Response Rate at Endpoint
timeFrame: Day 85 or the last post-baseline assessment
measure: PANSS Positive Subscale Mean Change From Baseline to Endpoint
timeFrame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
measure: PANSS Negative Subscale Mean Change From Baseline to Endpoint
timeFrame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
measure: PANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint
timeFrame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Other outcomes:
measure: PSP Total Score From Baseline at Each Post-baseline Assessment Time Point
timeFrame: Day 1 (Baseline), Days 29, 57 and 85 (or the last post-baseline assessment)
measure: SWN-20 Total Score From Baseline at Each Post-baseline Assessment Time Point
timeFrame: Day 1 (Baseline), Days 29, 57 and 85 or the last post-baseline assessment
measure: Plasma PK Parameters
timeFrame: Day 3 and Day 29 after Dose 1, 2 and 3
Locations:
city: Rogers
country: United States
facility: Woodland Research Northwest
state: Arkansas
city: Cerritos
country: United States
facility: CIMU Bellflower
state: California
city: Garden Grove
country: United States
facility: Collaborative Neuroscience Network, LLC.
state: California
city: Lemon Grove
country: United States
facility: Synergy Research San Diego
state: California
city: Long Beach
country: United States
facility: Apostle Clinical Trials
state: California
city: Orange
country: United States
facility: NRC Research Institute
state: California
city: Pico Rivera
country: United States
facility: CNRI-Los Angeles LLC
state: California
city: San Diego
country: United States
facility: CNRI-San Diego
state: California
city: Hialeah
country: United States
facility: Galiz Research
state: Florida
city: Hollywood
country: United States
facility: Innovative Clinical Research Inc.
state: Florida
city: Atlanta
country: United States
facility: Atlanta Center for Medical Research
state: Georgia
city: Gaithersburg
country: United States
facility: CBH Health LLC
state: Maryland
city: Flowood
country: United States
facility: Precise Research Centers MS
state: Mississippi
city: Las Vegas
country: United States
facility: Altea Research Institute
state: Nevada
city: Berlin
country: United States
facility: Hassman Research Institute
state: New Jersey
city: Dayton
country: United States
facility: Midwest Clinical Research Center
state: Ohio
city: Charleston
country: United States
facility: Carolina Clinical Triasl Inc
state: South Carolina
city: Austin
country: United States
facility: Community Clinical Research Inc.
state: Texas
city: DeSoto
country: United States
facility: InSite Clinical Research
state: Texas
city: Richardson
country: United States
facility: Pillar Clinical Research LLC
state: Texas
city: Dnipro
country: Ukraine
facility: Regional Clinical Hospital n.a I.I. Mechnicov
city: Kharkiv
country: Ukraine
facility: Kharkiv Regional Clinical Psychiatric Hospital
city: Kharkiv
country: Ukraine
facility: Public Healthcare Institution "Kharkiv Regional Clinical Psychiatric Hospital No. 3", Center of Urgent Psychiatry
city: Kherson
country: Ukraine
facility: Kherson Regional Psychiatric Hospital
city: Kiev
country: Ukraine
facility: Kiev City Psychiatric Hospital No. 2
city: Kiev
country: Ukraine
facility: Kyiv Regional Medical Association "Psykhiatriya" in Kyiv
city: Lviv
country: Ukraine
facility: CI Lviv Regional Clinical Psychiatric Hospital. Department 20
city: Lviv
country: Ukraine
facility: CI Lviv Regional Clinical Psychiatric Hospital. Department 25
city: Odesa
country: Ukraine
facility: Odesa Regional Medical Centre of Mental Health
city: Poltava
country: Ukraine
facility: Maltsev Regional Clinical Psychiatric Ho
city: Vinnytsia
country: Ukraine
facility: N.I. Pyrogov Vinnytsya Natl Medical University
Study officials:
affiliation: CBH Health LLC
name: Robert Litman
role: PRINCIPAL_INVESTIGATOR
affiliation: CI Lviv Regional Clinical Psychiatric Hospital. Department 25
name: Yuriy Filts
role: PRINCIPAL_INVESTIGATOR
References:
citation: Correll CU, Litman RE, Filts Y, Llaudo J, Naber D, Torres F, Martinez J. Efficacy and safety of once-monthly Risperidone ISM(R) in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020 Nov 25;6(1):37. doi: 10.1038/s41537-020-00127-y.